[go: up one dir, main page]

CU24173B1 - Compuestos derivados de tieno [2,3-d] pirimidina para el tratamiento de la arritmia - Google Patents

Compuestos derivados de tieno [2,3-d] pirimidina para el tratamiento de la arritmia

Info

Publication number
CU24173B1
CU24173B1 CUP2013000124A CU20130124A CU24173B1 CU 24173 B1 CU24173 B1 CU 24173B1 CU P2013000124 A CUP2013000124 A CU P2013000124A CU 20130124 A CU20130124 A CU 20130124A CU 24173 B1 CU24173 B1 CU 24173B1
Authority
CU
Cuba
Prior art keywords
salt
pyrimidine
treatment
compounds derived
ester
Prior art date
Application number
CUP2013000124A
Other languages
English (en)
Other versions
CU20130124A7 (es
Inventor
Derek Edward John
John Ford
Original Assignee
Xention Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44071904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU24173(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Xention Ltd filed Critical Xention Ltd
Publication of CU20130124A7 publication Critical patent/CU20130124A7/es
Publication of CU24173B1 publication Critical patent/CU24173B1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuestos derivados de [2,3d] pirimidina para el tratamiento de la arritmia caracterizado porque es de fórmula (Ia) ESPACIO PARA LA FÓRMULA o un éster o sal del mismo aceptable farmacéuticamente en donde el éster es un éster en el cual el átomo de hidrógeno del grupo alcohol es reemplazado por C(O)C1-6 alquilo y la sal es una sal de adición del ácido de un ácido inorgánico o un ácido orgánico o es una sal básica seleccionada de una sal metálica o una sal formada con amonio o una amina orgánica farmacéuticamente estable o base heterocíclica.
CUP2013000124A 2011-04-01 2012-03-29 Compuestos derivados de tieno [2,3-d] pirimidina para el tratamiento de la arritmia CU24173B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1105659.5A GB201105659D0 (en) 2011-04-01 2011-04-01 Compounds
PCT/GB2012/050710 WO2012131379A1 (en) 2011-04-01 2012-03-29 Thieno [2, 3 -d] pyrimidine derivatives and their use to treat arrhythmia

Publications (2)

Publication Number Publication Date
CU20130124A7 CU20130124A7 (es) 2014-01-29
CU24173B1 true CU24173B1 (es) 2016-04-25

Family

ID=44071904

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2013000124A CU24173B1 (es) 2011-04-01 2012-03-29 Compuestos derivados de tieno [2,3-d] pirimidina para el tratamiento de la arritmia

Country Status (42)

Country Link
US (1) US9249155B2 (es)
EP (1) EP2694518B1 (es)
JP (1) JP5826374B2 (es)
KR (1) KR20140023332A (es)
CN (1) CN103492392B (es)
AP (1) AP2013007198A0 (es)
AR (1) AR088735A1 (es)
AU (1) AU2012235882B2 (es)
BR (1) BR112013025236A2 (es)
CA (1) CA2831493A1 (es)
CL (1) CL2013002789A1 (es)
CO (1) CO6801756A2 (es)
CR (1) CR20130488A (es)
CU (1) CU24173B1 (es)
CY (1) CY1117025T1 (es)
DK (1) DK2694518T3 (es)
EA (1) EA201301111A1 (es)
EC (1) ECSP13012988A (es)
ES (1) ES2558563T3 (es)
GB (1) GB201105659D0 (es)
GT (1) GT201300225A (es)
HR (1) HRP20151340T1 (es)
HU (1) HUE028438T2 (es)
IL (1) IL228555A0 (es)
MA (1) MA35064B1 (es)
ME (1) ME02314B (es)
MX (1) MX335937B (es)
NI (1) NI201300100A (es)
PE (1) PE20141021A1 (es)
PH (1) PH12013501952A1 (es)
PL (1) PL2694518T3 (es)
PT (1) PT2694518E (es)
RS (1) RS54458B1 (es)
RU (1) RU2013148627A (es)
SG (1) SG193578A1 (es)
SI (1) SI2694518T1 (es)
SM (1) SMT201500322B (es)
TN (1) TN2013000377A1 (es)
TW (1) TWI516265B (es)
UA (1) UA110131C2 (es)
WO (1) WO2012131379A1 (es)
ZA (1) ZA201307085B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014078957A1 (en) * 2012-11-20 2014-05-30 The Royal Institution For The Advancement Of Learning/Mcgill University Thienopyrimidine inhibitors of farnesyl and/or geranylgeranyl pyrophosphate synthase
CN109311868B (zh) 2015-12-22 2022-04-01 尚医治疗有限责任公司 用于治疗癌症和炎性疾病的化合物
CN106727587A (zh) * 2016-11-28 2017-05-31 李娜 一种治疗心律失常的药物组合物
EP3642209B1 (en) 2017-06-21 2023-11-29 Shy Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
EP3898609A1 (en) 2018-12-19 2021-10-27 Shy Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH317906A (de) 1953-09-16 1956-12-15 Sandoz Ag Verfahren zur Herstellung von 1-Amino-4-oxyanthrachinonsulfonsäuren
AU521790B2 (en) 1977-05-23 1982-04-29 Ici Australia Limited Process for eradication of ticks
ZA782648B (en) 1977-05-23 1979-06-27 Ici Australia Ltd The prevention,control or eradication of infestations of ixodid ticks
DD226893A1 (de) 1981-12-15 1985-09-04 Ralf Boehm Verfahren zur herstellung von arylaminosubstituierten thieno 2,3-d pyrimidinen
IL112567A (en) 1994-02-10 2000-02-29 Wyeth John & Brother Ltd Substituted quinolines their preparation and pharmaceutical compositions containing them
IL112569A (en) 1994-02-10 1999-12-22 Wyeth John & Brother Ltd Pharmaceutical compositions comprising cyclohexylamine derivatives certain such novel compounds and their preparation
IL112566A (en) 1994-02-10 2000-10-31 Wyeth John & Brother Ltd Substituted quinolinones and pharmaceutical compositions containing them
IL112568A0 (en) 1994-02-10 1995-05-26 Wyeth John & Brother Ltd Substituted quinolines, their preparation and pharmaceutical compositions containing them
EP0846119B1 (en) 1995-08-17 2002-11-13 Takeda Chemical Industries, Ltd. Thienopyrimidine derivatives, their production and use as endothelin antagonists
HUP9902456A3 (en) 1996-07-26 2002-04-29 Nissan Chemical Ind Ltd Chroman derivatives
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
US5969017A (en) 1996-10-31 1999-10-19 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US5935945A (en) 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
RU2116309C1 (ru) 1997-02-13 1998-07-27 Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского 4-[(бензо-2,1,3-тиадиазолил-4)амино]-5,6,7,8-тетрагидробензотиено [2,3-d]пиримидин, обладающий противогельминтной активностью при ларвальном альвеолярном эхинококкозе
US6333337B1 (en) 1998-01-27 2001-12-25 Icagen, Inc. Potassium channel inhibitors
JP2002517385A (ja) 1998-06-05 2002-06-18 イカゲン インク. カリウムチャネル阻害剤
WO2000012492A1 (en) 1998-09-01 2000-03-09 Nissan Chemical Industries, Ltd. Benzoxazine derivatives
US6194458B1 (en) 1998-10-30 2001-02-27 Merck & Co., Inc. Benzamide potassium channel inhibitors
DE19929076A1 (de) 1999-06-25 2000-12-28 Aventis Pharma Gmbh Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
IL147968A0 (en) 1999-09-17 2002-09-12 Nissan Chemical Ind Ltd Benzopyran derivative
EP1214307B1 (en) 1999-09-24 2004-04-07 Nissan Chemical Industries, Ltd. 4-oxybenzopyran derivative
DE19947457A1 (de) 1999-10-02 2001-04-05 Aventis Pharma Gmbh 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
US6531495B1 (en) 1999-10-02 2003-03-11 Aventis Pharma Deutschland Gmbh 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
WO2001025224A1 (en) 1999-10-05 2001-04-12 Nissan Chemical Industries, Ltd. 4-oxybenzopyran derivative
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
WO2001046155A1 (en) 1999-12-21 2001-06-28 Icagen, Inc. Potassium channel inhibitors
US6870055B2 (en) 2000-09-20 2005-03-22 Merck & Co., Inc. Isoquinolinone potassium channels inhibitors
DE10054481A1 (de) 2000-11-03 2002-05-08 Aventis Pharma Gmbh Acylaminoalkyl-substituierte Benzolsulfonamidderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10059418A1 (de) 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10060807A1 (de) 2000-12-07 2002-06-20 Aventis Pharma Gmbh Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10061876A1 (de) 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10104802A1 (de) 2001-02-02 2002-08-08 Merck Patent Gmbh Pharmazeutische Formulierungen enthaltend Thienopirimidine und Endothelin-Rezeptor-Antagonisten (1)
CN1489467A (zh) 2001-02-02 2004-04-14 Ĭ��ר���ɷ����޹�˾ 含吡唑并[4,3-d]嘧啶和内皮素受体拮抗剂或者噻吩并嘧啶和内皮素受体拮抗剂的药物制剂
TW589305B (en) 2001-02-14 2004-06-01 Nissan Chemical Ind Ltd 4-aminobenzopyran derivatives
DE10121002A1 (de) 2001-04-28 2002-11-14 Aventis Pharma Gmbh Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10128331A1 (de) 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
RU2291867C2 (ru) 2001-06-25 2007-01-20 Ниссан Кемикал Индастриз, Лтд. Замещенные производные бензопирана против аритмии
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
CN1823071B (zh) 2003-06-11 2012-12-19 润生有限公司 用作钾通道抑制剂的噻吩并嘧啶衍生物
ZA200600197B (en) * 2003-07-02 2007-06-27 Vertex Pharma Pyrimidines useful as modulators of voltage-gated ion channels
JP2007517793A (ja) 2004-01-06 2007-07-05 大正製薬株式会社 環状アミノ基によって置換されたチエノピリミジン及びチエノピリジン誘導体
US7776867B2 (en) 2004-06-29 2010-08-17 Amgen Inc. Furanopyrimidines
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
EP1879899B1 (en) 2004-12-09 2010-08-04 Xention Limited Thienopyridine derivatives as potassium channel inhibitors
WO2007084815A2 (en) 2006-01-19 2007-07-26 Janssen Pharmaceutica, N.V. Substituted thienopyrimidine kinase inhibitors
AU2007258313A1 (en) * 2006-06-12 2007-12-21 Vertex Pharmaceuticals Incorporated Thienopyrimidines useful as modulators of ion channels
DE102009039893B4 (de) 2009-09-03 2012-03-29 Bundesanstalt für Materialforschung und -Prüfung (BAM) Verwendung eines Brennstoffs in einem selbstunterhaltenden pulsierenden Sauerstoff-Brennstoff-Verbrennungsprozess

Also Published As

Publication number Publication date
RU2013148627A (ru) 2015-05-10
TN2013000377A1 (en) 2015-01-20
SG193578A1 (en) 2013-10-30
EP2694518A1 (en) 2014-02-12
SI2694518T1 (sl) 2016-02-29
ME02314B (me) 2016-06-20
WO2012131379A1 (en) 2012-10-04
ES2558563T3 (es) 2016-02-05
DK2694518T3 (en) 2015-11-09
PE20141021A1 (es) 2014-08-30
CO6801756A2 (es) 2013-11-29
CY1117025T1 (el) 2017-04-05
PT2694518E (pt) 2016-02-05
MX2013011301A (es) 2014-04-16
JP5826374B2 (ja) 2015-12-02
TWI516265B (zh) 2016-01-11
CA2831493A1 (en) 2012-10-04
NZ615621A (en) 2015-01-30
BR112013025236A2 (pt) 2019-09-24
CN103492392A (zh) 2014-01-01
AR088735A1 (es) 2014-07-02
AU2012235882B2 (en) 2015-08-06
AU2012235882A1 (en) 2013-05-02
HK1193806A1 (zh) 2014-10-03
MA35064B1 (fr) 2014-04-03
SMT201500322B (it) 2016-02-25
UA110131C2 (ru) 2015-11-25
TW201244720A (en) 2012-11-16
PL2694518T3 (pl) 2016-03-31
ZA201307085B (en) 2015-04-29
IL228555A0 (en) 2013-12-31
AP2013007198A0 (en) 2013-10-31
KR20140023332A (ko) 2014-02-26
HK1193096A1 (zh) 2014-09-12
PH12013501952A1 (en) 2018-04-11
GB201105659D0 (en) 2011-05-18
NI201300100A (es) 2014-01-07
CR20130488A (es) 2013-12-06
MX335937B (es) 2016-01-04
HUE028438T2 (en) 2017-02-28
ECSP13012988A (es) 2013-12-31
CU20130124A7 (es) 2014-01-29
EP2694518B1 (en) 2015-10-07
GT201300225A (es) 2014-12-30
HRP20151340T1 (hr) 2016-02-26
EA201301111A1 (ru) 2014-02-28
US20140206703A1 (en) 2014-07-24
US9249155B2 (en) 2016-02-02
RS54458B1 (sr) 2016-06-30
CN103492392B (zh) 2015-11-25
CL2013002789A1 (es) 2014-07-18
JP2014509637A (ja) 2014-04-21

Similar Documents

Publication Publication Date Title
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
PH12014500883A1 (en) Uracil derivatives as axl and c-met kinase inhibitors
EA201390884A1 (ru) Азабензимидазолы в качестве противовирусных средств в отношении респираторного синцитиального вируса
MD20180040A2 (ro) Inhibitori ai virusului hepatic C
EA201491456A1 (ru) Соединения-ингибиторы raf
PE20190973A1 (es) Compuestos de tetrahidropirazolopirimidina
PH12015502232A1 (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
PH12016500169A1 (en) Polymorph of syk inhibitors
CY1118478T1 (el) Παραγωγα τυπου αζαϊνδαζολιου ή διαζαϊνδαζολιου για τη θεραπεια του πονου
WO2014031872A3 (en) Small molecule inhibitors for treating parasitic infections
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
CR20130023A (es) Pirazolo[1,5-a]pirimidinas para tratamiento antiviral
MD20140072A2 (ro) Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
CR20150663A (es) Derivados de diazacarbazol como ligandos de tau para pet
MX368178B (es) Compuestos de ácido dimetilbenzoico.
MX388853B (es) Derivados de heteroarilpiperidina y de heteroarilpiperazina como fungicidas.
NZ712660A (en) Dicarboxylic acid compound
EA201592268A1 (ru) Дигидропиридиноновые ингибиторы mgat2
CU24173B1 (es) Compuestos derivados de tieno [2,3-d] pirimidina para el tratamiento de la arritmia
MX2015015841A (es) Compuestos de fenoxietil dihidro-1h-isoquinolina.
UA113086C2 (xx) Піразольні сполуки як інгібітори sglt1
ZA201604932B (en) N1-(3,3,3-trifluoro-2-hydroxo-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase
EA201490383A1 (ru) Способ получения ситаглиптина и его фармацевтически приемлемых солей
AR092772A1 (es) Derivado de 7-azaindol
SG10201901578UA (en) Processes for the preparation of pyrimidinylcyclopentane compounds